Literature DB >> 10964542

N36, a synthetic N-terminal heptad repeat domain of the HIV-1 envelope protein gp41, is an activator of human phagocytes.

Y Le1, S Jiang, J Hu, W Gong, S Su, N M Dunlop, W Shen, B Li, J Ming Wang.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) envelope protein gp41 mediates viral fusion with human host cells. In this study we show that N36, a synthetic peptide derived from the N-terminus of gp41, induced directional migration and calcium mobilization in human monocytes and neutrophils. The activity of N36 on phagocytes was pertussis toxin sensitive, suggesting involvement of a Gi-coupled seven-transmembrane receptor(s). Since high concentrations of the bacterial chemotactic peptide fMet-Leu-Phe (fMLF) partially desensitized the calcium mobilizing activity of N36 in phagocytes, we postulated that N36 might use a low-affinity fMLF receptor. By using cells stably expressing fMLF receptor FPR or FPRL1, we demonstrate that N36 uses FPRL1 as a functional receptor. Our results suggest that HIV-1 gp41 may contain a fragment(s) that activates the innate host immune cells through FPRL1. Since the activation of FPRL1 in monocytes has been shown to heterologously desensitize chemokine receptors, the reduced phagocyte response to chemoattractants seen in AIDS patients may be attributed, at least in part, to heterologous desensitization. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10964542     DOI: 10.1006/clim.2000.4896

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  13 in total

1.  Duplex high-throughput flow cytometry screen identifies two novel formylpeptide receptor family probes.

Authors:  Susan M Young; Cristian M Bologa; Dan Fara; Bj K Bryant; Juan Jacob Strouse; Jeffrey B Arterburn; Richard D Ye; Tudor I Oprea; Eric R Prossnitz; Larry A Sklar; Bruce S Edwards
Journal:  Cytometry A       Date:  2009-03       Impact factor: 4.355

2.  The HIV-1 gp41 ectodomain is cleaved by matriptase to produce a chemotactic peptide that acts through FPR2.

Authors:  Matthew P Wood; Amy L Cole; Colleen R Eade; Li-Mei Chen; Karl X Chai; Alexander M Cole
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

Review 3.  Lipoxins: resolutionary road.

Authors:  Paola Maderna; Catherine Godson
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

Review 4.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

5.  Apolipoproteins and apolipoprotein mimetic peptides modulate phagocyte trafficking through chemotactic activity.

Authors:  Jennifer H Madenspacher; Kathleen M Azzam; Wanghua Gong; Kymberly M Gowdy; Michael P Vitek; Daniel T Laskowitz; Alan T Remaley; Ji Ming Wang; Michael B Fessler
Journal:  J Biol Chem       Date:  2012-11-01       Impact factor: 5.157

6.  A novel fluorescent cross-reactive formylpeptide receptor/formylpeptide receptor-like 1 hexapeptide ligand.

Authors:  J Jacob Strouse; Susan M Young; Hugh D Mitchell; Richard D Ye; Eric R Prossnitz; Larry A Sklar; Bruce S Edwards
Journal:  Cytometry A       Date:  2009-03       Impact factor: 4.355

Review 7.  Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists.

Authors:  Fabio Cattaneo; Melania Parisi; Rosario Ammendola
Journal:  Int J Mol Sci       Date:  2013-04-02       Impact factor: 5.923

Review 8.  Therapeutic Potential of Annexin A1 in Ischemia Reperfusion Injury.

Authors:  Junaid Ansari; Gaganpreet Kaur; Felicity N E Gavins
Journal:  Int J Mol Sci       Date:  2018-04-16       Impact factor: 5.923

Review 9.  The Formyl Peptide Receptors: Diversity of Ligands and Mechanism for Recognition.

Authors:  Hui-Qiong He; Richard D Ye
Journal:  Molecules       Date:  2017-03-13       Impact factor: 4.411

10.  Myricetin antagonizes semen-derived enhancer of viral infection (SEVI) formation and influences its infection-enhancing activity.

Authors:  Ruxia Ren; Shuwen Yin; Baolong Lai; Lingzhen Ma; Jiayong Wen; Xuanxuan Zhang; Fangyuan Lai; Shuwen Liu; Lin Li
Journal:  Retrovirology       Date:  2018-07-16       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.